{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:01:08Z","timestamp":1770717668779,"version":"3.49.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:p>While interferon\u2010based therapy has excellent efficacy in acute and recent hepatitis C virus (HCV) infection, the side effect profile limits implementation. Sofosbuvir and ribavirin for 12\u201024 weeks is safe and well tolerated in chronic HCV, with efficacy dependent on genotype and disease stage. The aim of this study was to assess the efficacy of sofosbuvir and ribavirin for 6 weeks in individuals with recent HCV infection. In this open\u2010label study conducted in Australia and New Zealand, adults with recent HCV (duration of infection &lt;12 months) received sofosbuvir 400 mg daily and weight\u2010based ribavirin (&lt;75 kg, 1,000 mg\/day; \u226575 kg, 1,200 mg\/day) for 6 weeks. The primary efficacy endpoint was sustained virological response at posttreatment week 12 (SVR12). Nineteen participants commenced sofosbuvir and ribavirin (89% male, 74% with human immunodeficiency virus, 68% genotype 1a). Four (21%) reported a symptomatic HCV seroconversion illness, including 2 with jaundice. At baseline, median HCV RNA was 5.4 log<jats:sub>10<\/jats:sub> IU\/mL (interquartile range 4.4\u20106.8) and median estimated duration of infection was 37 weeks (interquartile range 27\u201041). At the end of treatment, HCV RNA was nonquantifiable in 89% (n = 17). SVR4 and SVR12 were 42% (n = 8) and 32% (n = 6), respectively. Treatment failure was due to nonresponse (n = 2), posttreatment relapse (n = 9), reinfection (n = 1), and loss to follow\u2010up (n = 1). The regimen was well tolerated with minimal hematological toxicity. SVR12 was related to baseline HCV RNA (\u22646 log<jats:sub>10<\/jats:sub> IU\/mL, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.018) and early on\u2010treatment viral kinetics (HCV RNA below the level of quantitation at week 1, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003). <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Six weeks of sofosbuvir and ribavirin was safe and well tolerated, but efficacy was suboptimal; further research is needed to determine whether more potent interferon\u2010free direct\u2010acting antiviral regimens will allow treatment duration to be shortened in recent, predominantly asymptomatic HCV infection. (H<jats:sc>epatology<\/jats:sc> 2016;64:1911\u20101921).<\/jats:p>","DOI":"10.1002\/hep.28844","type":"journal-article","created":{"date-parts":[[2016,9,17]],"date-time":"2016-09-17T15:35:29Z","timestamp":1474126529000},"page":"1911-1921","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":47,"title":["Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE\u2010C II study"],"prefix":"10.1097","volume":"64","author":[{"given":"Marianne","family":"Martinello","sequence":"first","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Gane","sequence":"additional","affiliation":[{"name":"Auckland Hospital,Auckland,New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hellard","sequence":"additional","affiliation":[{"name":"Burnet Institute,Melbourne,VIC,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Sasadeusz","sequence":"additional","affiliation":[{"name":"The Royal Melbourne Hospital,Melbourne,VIC,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital,Adelaide,SA,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Petoumenos","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Applegate","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Maire","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippa","family":"Marks","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Kirby Institute,University of New South Wales,Sydney,NSW,Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"hep28844-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.drugpo.2015.07.003","article-title":"Enhancing the detection and management of acute hepatitis C virus infection","volume":"26","year":"2015","journal-title":"Int J Drug Policy"},{"key":"hep28844-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL Recommendations on Treatment of Hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"hep28844-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/cid\/civ197","article-title":"Hepatitis C virus therapeutic development: in pursuit of \u201cperfectovir","volume":"60","year":"2015","journal-title":"Clin Infect Dis"},{"key":"hep28844-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep28844-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep28844-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK\u20105172) and elbasvir (MK\u20108742) in patients with hepatitis C virus and HIV co\u2010infection (C\u2010EDGE CO\u2010INFECTION): a non\u2010randomised, open\u2010label trial","volume":"2","year":"2015","journal-title":"Lancet HIV"},{"key":"hep28844-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1053\/j.gastro.2016.05.021","article-title":"Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3\/4A protease inhibitor GS\u20109857 in treatment\u2010naive or previously treated patients with HCV genotype 1 or 3 infections","volume":"151","year":"2016","journal-title":"Gastroenterology"},{"key":"hep28844-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.gastro.2009.09.019","article-title":"Effective treatment of injecting drug users with recently acquired hepatitis C virus infection","volume":"138","year":"2010","journal-title":"Gastroenterology"},{"key":"hep28844-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciw075","article-title":"Can hepatitis C virus (HCV) direct\u2010acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights","volume":"62","year":"2016","journal-title":"Clin Infect Dis"},{"key":"hep28844-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct\u2010acting antivirals as treatment for prevention","volume":"10","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"hep28844-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"hep28844-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep28844-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co\u2010infected with HIV (PHOTON\u20102): a multicentre, open\u2010label, non\u2010randomised, phase 3 study","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"hep28844-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2012.07.007","article-title":"Case definitions for acute hepatitis C virus infection: a systematic review","volume":"57","year":"2012","journal-title":"J Hepatol"},{"key":"hep28844-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity","volume":"38","year":"2004","journal-title":"Clin Infect Dis"},{"key":"hep28844-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2893.2006.00749.x","article-title":"Zidovudine use but not weight\u2010based ribavirin dosing impacts anaemia during HCV treatment in HIV\u2010infected persons","volume":"13","year":"2006","journal-title":"J Viral Hepat"},{"key":"hep28844-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/hep.27310","article-title":"Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada","volume":"60","year":"2014","journal-title":"Hepatology"},{"key":"hep28844-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"e0131437","DOI":"10.1371\/journal.pone.0131437","article-title":"The influence of hepatitis C virus genetic region on phylogenetic clustering analysis","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep28844-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1038\/ncomms7422","article-title":"Interferon\u2010\u03bb rs12979860 genotype and liver fibrosis in viral and non\u2010viral chronic liver disease","volume":"6","year":"2015","journal-title":"Nat Commun"},{"key":"hep28844-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"e1001092","DOI":"10.1371\/journal.pmed.1001092","article-title":"IL28B, HLA\u2010C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross\u2010sectional study","volume":"8","year":"2011","journal-title":"PLoS Med"},{"key":"hep28844-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1360-0443.1992.tb02719.x","article-title":"Development and validation of a multi\u2010dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index","volume":"87","year":"1992","journal-title":"Br J Addict"},{"key":"hep28844-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2006.03.019","article-title":"Validation of liquid\/liquid extraction method coupled with HPLC\u2010UV for measurement of ribavirin plasma levels in HCV\u2010positive patients","volume":"835","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"hep28844-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/cid\/cit799","article-title":"Telaprevir in the treatment of acute hepatitis C virus infection in HIV\u2010infected men","volume":"58","year":"2014","journal-title":"Clin Infect Dis"},{"key":"hep28844-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3851\/IMP3073","article-title":"Short duration response\u2010guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE\u2010C I studies","volume":"21","year":"2016","journal-title":"Antivir Ther"},{"key":"hep28844-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep28844-bib-0029-20241017","first-page":"736A","article-title":"Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study. Interim data","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep28844-bib-0031-20241017","article-title":"Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta\u2010analysis","year":"2016","journal-title":"Int J STD AIDS"},{"key":"hep28844-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1097\/QAD.0000000000000834","article-title":"Incidence of sexually transmitted hepatitis C virus infection in HIV\u2010positive men who have sex with men","volume":"29","year":"2015","journal-title":"AIDS"},{"key":"hep28844-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1097\/QAD.0b013e32836381cc","article-title":"Hepatitis C virus reinfection incidence and treatment outcome among HIV\u2010positive MSM","volume":"27","year":"2013","journal-title":"AIDS"},{"key":"hep28844-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/QAD.0b013e32834bac44","article-title":"Alarming incidence of hepatitis C virus re\u2010infection after treatment of sexually acquired acute hepatitis C virus infection in HIV\u2010infected MSM","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"hep28844-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/hiv.12127","article-title":"Multiple hepatitis C virus (HCV) reinfections in HIV\u2010positive men who have sex with men: no influence of HCV genotype switch or interleukin\u201028B genotype on spontaneous clearance","volume":"15","year":"2014","journal-title":"HIV Med"},{"key":"hep28844-bib-0036-20241017","article-title":"Elbasvir\u2010Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial","journal-title":"Annals of internal medicine"},{"issue":"Suppl. 2","key":"hep28844-bib-0038-20241017","first-page":"S80","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta\u2010analysis","volume":"57","year":"2013","journal-title":"Clin Infect Dis"},{"key":"hep28844-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cit938","article-title":"Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study","volume":"58","year":"2014","journal-title":"Clin Infect Dis"},{"key":"hep28844-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","article-title":"Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence","volume":"28","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"hep28844-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","article-title":"Prioritization of HCV treatment in the direct\u2010acting antiviral era: an economic evaluation","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep28844-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","year":"2015","journal-title":"Ann Intern Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28844","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201612000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:35:29Z","timestamp":1729211729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201612000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.28844","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]},"assertion":[{"value":"2016-05-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}